MorphoSys AG - ADR

Name: MorphoSys AG - ADR Share Price Today, Stock Analysis, Annual Report | Value Research
Brand: MorphoSys AG - ADR

Stock Card

$18.96

$-- (--%)

As on 09-Aug-2024 09:30EDT

Market cap

$2,856 Mln

Revenue (TTM)

$204 Mln

P/E Ratio

P/B Ratio

53.8

Div. Yield

0 %

MorphoSys AG - ADR Share Price

Compare

High: Low: Return:

Price P/E Ratio P/B Ratio

Stock Range

Today’s Range

Low: 18.96 High: 18.96

52 Week Range

Low: -- High: --

Liquidity

Low Moderate High

Fundamentals

Net Profit (TTM)

$-194 Mln
ROE

-1.8 %
ROCE

-- %
Industry P/E

--
EV/EBITDA

-0.3
Debt to Equity

0
Book Value

$--
EPS

$-3.2
Face value

--
Shares outstanding

150,651,008

10 Years Aggregate

CFO

€-1,344.92 Mln

EBITDA

€-226.09 Mln

Net Profit

€-1,034.91 Mln

Company	YTD	1 Month	3 Months	1 Year	3 Years	5 Years	10 Years
MorphoSys AG - ADR	91.5	1.7	5.6	152.5	12.7	-9.7	--
BSE Sensex^*	-9.1	1.1	1.2	-4.8	5.8	6.6	10.7
S&P Small-Cap 600^#	-5.8	-5.3	-13.7	-6.3	5.3	3.0	5.5

As on 09-Aug-2024 | *As on 27-Aug-2026 | #As on 26-Oct-2023

Company	2023	2022	2021	2020	2019
MorphoSys AG - ADR	176.5	-62.0	-66.8	-20.5	41.0
S&P Small-Cap 600	13.9	-17.4	25.3	9.6	20.9
BSE Sensex	18.7	4.4	22.0	15.8	14.4

Essential Checks

View Details

Is there a threat to the company's solvency?

Can creative accounting be detected through the financial numbers?

How did the company perform in the last one year?

Financials

View Details

Key Ratios

View Details

Shareholding Pattern

View Details

About MorphoSys AG - ADR

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that... is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany. As of May 30, 2024, MorphoSys AG operates as a subsidiary of Novartis BidCo AG. Read more

Chairman of Management Board, MD & CEO

Dr. Jean-Paul Kress M.D.
Chairman of Management Board, MD & CEO

Dr. Jean-Paul Kress M.D.
Headquarters

Planegg
Website

https://www.morphosys.com

FAQs for MorphoSys AG - ADR

What is the current share price of MorphoSys AG - ADR Today?

The share price of MorphoSys AG - ADR is $18.96 (NASDAQ) as of 09-Aug-2024 09:30 EDT. MorphoSys AG - ADR has given a return of 12.66% in the last 3 years.

What is the current PB & PE ratio of MorphoSys AG - ADR?

Since, TTM earnings of MorphoSys AG - ADR is negative, P/E ratio is not available.
The P/B ratio of MorphoSys AG - ADR is 53.81 times as on 13-Aug-2024, a 1016 premium to its peers’ median range of 4.82 times.

PE & PB ratio at the end of financial year.